Baxter International (NYSE:BAX)‘s stock had its “buy” rating reiterated by equities researchers at Piper Jaffray Companies in a research note issued to investors on Tuesday, TipRanks reports.

Other equities analysts also recently issued research reports about the stock. JPMorgan Chase & Co. boosted their price target on shares of Baxter International from $80.00 to $88.00 and gave the company an “overweight” rating in a report on Monday, May 13th. KeyCorp assumed coverage on shares of Baxter International in a report on Tuesday, June 25th. They issued a “sector weight” rating on the stock. Credit Suisse Group lifted their price objective on shares of Baxter International from $84.00 to $95.00 and gave the company an “outperform” rating in a research report on Friday, July 26th. Zacks Investment Research raised shares of Baxter International from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research note on Friday, June 21st. Finally, Royal Bank of Canada set a $87.00 target price on shares of Baxter International and gave the stock a “hold” rating in a research report on Friday, July 26th. Four analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Baxter International presently has an average rating of “Buy” and a consensus target price of $85.27.

Baxter International stock traded up $0.80 during midday trading on Tuesday, hitting $86.71. 2,522,811 shares of the stock were exchanged, compared to its average volume of 2,681,903. The firm has a market cap of $44.56 billion, a P/E ratio of 28.43, a P/E/G ratio of 2.02 and a beta of 1.00. Baxter International has a 1 year low of $61.05 and a 1 year high of $89.93. The company has a debt-to-equity ratio of 0.72, a current ratio of 2.78 and a quick ratio of 2.10. The company has a 50 day moving average price of $86.31 and a two-hundred day moving average price of $80.10.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.81 by $0.08. The business had revenue of $2.84 billion during the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a return on equity of 21.21% and a net margin of 14.28%. The business’s quarterly revenue was down .1% on a year-over-year basis. During the same period in the previous year, the business earned $0.77 EPS. As a group, analysts predict that Baxter International will post 3.37 EPS for the current year.

In related news, Director John D. Forsyth sold 1,320 shares of the business’s stock in a transaction that occurred on Thursday, June 13th. The stock was sold at an average price of $78.21, for a total transaction of $103,237.20. Following the sale, the director now owns 32,779 shares of the company’s stock, valued at $2,563,645.59. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Jacqueline Kunzler sold 5,934 shares of the company’s stock in a transaction that occurred on Thursday, September 5th. The stock was sold at an average price of $88.12, for a total value of $522,904.08. Following the completion of the sale, the senior vice president now owns 3,089 shares of the company’s stock, valued at $272,202.68. The disclosure for this sale can be found here. Insiders sold a total of 15,797 shares of company stock valued at $1,370,513 in the last quarter. 0.70% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. Stonebridge Capital Advisors LLC grew its holdings in Baxter International by 4.3% during the second quarter. Stonebridge Capital Advisors LLC now owns 2,886 shares of the medical instruments supplier’s stock worth $236,000 after acquiring an additional 120 shares during the period. SeaCrest Wealth Management LLC grew its stake in shares of Baxter International by 2.0% in the 2nd quarter. SeaCrest Wealth Management LLC now owns 6,117 shares of the medical instruments supplier’s stock worth $501,000 after purchasing an additional 122 shares during the last quarter. Baker Ellis Asset Management LLC grew its stake in shares of Baxter International by 8.3% in the 2nd quarter. Baker Ellis Asset Management LLC now owns 1,625 shares of the medical instruments supplier’s stock worth $133,000 after purchasing an additional 125 shares during the last quarter. Boston Private Wealth LLC grew its stake in shares of Baxter International by 1.8% in the 2nd quarter. Boston Private Wealth LLC now owns 7,346 shares of the medical instruments supplier’s stock worth $602,000 after purchasing an additional 129 shares during the last quarter. Finally, Brookstone Capital Management raised its holdings in shares of Baxter International by 4.0% in the 2nd quarter. Brookstone Capital Management now owns 3,422 shares of the medical instruments supplier’s stock worth $280,000 after purchasing an additional 131 shares in the last quarter. Institutional investors own 83.42% of the company’s stock.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

See Also: Fundamental Analysis – How It Helps Investors

Analyst Recommendations for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.